Pharmacogenetic Aspects of Antipsychotic Drug-induced Weight Gain - A Critical Review
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Treatment with several antipsychotic drugs can result in weight gain, which may lead to further morbidity such as type 2 diabetes and cardiovascular disease via the development of metabolic syndrome. These important and problematic metabolic consequences of antipsychotic drug treatment probably reflect a pharmacological disruption of the mechanisms involved in control of food intake and body weight. The extent of weight gain following antipsychotic drug treatment shows substantial variability between individuals, due in part to genetic factors. Common functional polymorphisms in many candidate genes implicated in the control of body weight and various aspects of energy and lipid metabolism have been investigated for association with weight gain in subjects receiving antipsychotic drug treatment, and with metabolic pathology in chronic schizophrenia. Perhaps the strongest and most replicated findings are the associations with promoter polymorphisms in the 5-HT2C receptor and leptin genes, although many other possible genetic risk factors, including polymorphisms in the fat mass and obesity associated (FTO)gene and genes for the alpha2A adrenoceptor and melanocortin4 receptor, have been reported. Genome-wide association studies (GWAS) have also addressed antipsychotic-induced weight gain and other indicators of metabolic disturbances. However there is as yet little consistency between these studies or between GWAS and classical candidate gene approaches. Identifying common genetic factors associated with drug-induced weight gain and its metabolic consequences may provide opportunities for personalized medicine in the predictive assessment of metabolic risk as well as indicating underlying physiological mechanisms.
Abstract
Treatment with several antipsychotic drugs can result in weight gain, which may lead to further morbidity such as type 2 diabetes and cardiovascular disease via the development of metabolic syndrome. These important and problematic metabolic consequences of antipsychotic drug treatment probably reflect a pharmacological disruption of the mechanisms involved in control of food intake and body weight. The extent of weight gain following antipsychotic drug treatment shows substantial variability between individuals, due in part to genetic factors. Common functional polymorphisms in many candidate genes implicated in the control of body weight and various aspects of energy and lipid metabolism have been investigated for association with weight gain in subjects receiving antipsychotic drug treatment, and with metabolic pathology in chronic schizophrenia. Perhaps the strongest and most replicated findings are the associations with promoter polymorphisms in the 5-HT2C receptor and leptin genes, although many other possible genetic risk factors, including polymorphisms in the fat mass and obesity associated (FTO)gene and genes for the alpha2A adrenoceptor and melanocortin4 receptor, have been reported. Genome-wide association studies (GWAS) have also addressed antipsychotic-induced weight gain and other indicators of metabolic disturbances. However there is as yet little consistency between these studies or between GWAS and classical candidate gene approaches. Identifying common genetic factors associated with drug-induced weight gain and its metabolic consequences may provide opportunities for personalized medicine in the predictive assessment of metabolic risk as well as indicating underlying physiological mechanisms.
참고문헌 (48)
- Osborn DP, "Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Rsearch Database", Arch Gen Psychiatry, 64, pp.242~249 (2007)
- Allison DB, "Antipsychotic-induced weight gain: a comprehensive research synthesis", Am J Psychiatry, 156, pp.1686~1696 (1999)
- Parsons B, "Weight effects associated with antipsychotics: a comprehensive database analysis", Schizophr Res, 110, pp.103~110 (2009)
- Gebhardt S, "Body weight gain induced by atypical antipsychotics: an extension of the monozygotic twin and sib pair study", J Clin Pharm Ther, 35, pp.207~211 (2010)
- Lett TA, "Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications", Mol Psychiatry, 17, pp.242~266 (2012)
- Reynolds GP, "The impact of pharmacogenetics on the development and use of antipsychotic drugs", Drug Discov Today, 12, pp.953~959 (2007)
- Arranz MJ, "Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research", Mol Psychiatry, 12, pp.707~747 (2007)
- Reynolds GP, "Metabolic side effects of antipsychotic drug treatment-pharmacological mechanisms", Pharmacol Ther, 125, pp.169~179 (2010)
- Reynolds GP, "Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism", Lancet, 359, pp.2086~2087 (2002)
- Templeman LA, "Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis", Pharmacogenet Genomics, 15, pp.195~200 (2005)
- Ellingrod VL, "Weight gain associated with the -759C", T polymorphism of the 5HT2C receptor and olanzapine, 2005, pp.134B, 76~78
- Miller DD, "Clozapine-induced weight gain associated with the 5HT2C receptor -759C", T polymorphism, 2005, pp.133B, 97~100
- Reynolds GP, "Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain", Am J Psychiatry, 160, pp.677~679 (2003)
- Young In Chung, "Association between Clozapine-induced Weight Gain and Serotonin 5-HT2C Receptor Gene Polymorphism in Korean Schizophrenic Patients", Clinical Psychopharmacology and Neuroscience, 2(1), pp.11~15 (2004), 대한정신약물학회
- Sicard MN, "Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: an update and metaanalysis", Pharmacogenomics, 11, pp.1561~1571 (2010)
- Hill MJ, "Functional consequences of two HTR2C polymorphisms associated with antipsychotic-induced weight gain", Pharmacogenomics, 12, pp.727~734 (2011)
- Hill MJ, "5-HT2C receptor gene polymorphisms associated with antipsychotic drug action alter promoter activity", Brain Res, 1149, pp.14~17 (2007)
- Mammè~s O, "Association of the G-2548A polymorphism in the 5' region of the LEP gene with overweight", Ann Hum Genet, 64, pp.391~394 (2000)
- Zhang ZJ, "Association of a polymorphism in the promoter region of the serotonin 5-HT2C receptor gene with tardive dyskinesia in patients with schizophrenia", Mol Psychiatry, 7, pp.670~671 (2002)
- Kuo PH, "Polymorphisms of INSIG2, MC4R, and LEP are associated with obesity- and metabolic-related traits in schizophrenic patients", J Clin Psychopharmacol, 31, pp.705~711 (2011)
- Brandl EJ, "Association study of polymorphisms in leptin and leptin receptor genes with antipsychotic-induced body weight gain", Prog Neuropsychopharmacol Biol Psychiatry (2012)
- Zhang ZJ, "No association of antipsychotic agent-induced weight gain with a DA receptor gene polymorphism and therapeutic response", Acta Pharmacol Sin, 24, pp.235~240 (2003)
- Hong CJ, "Genetic variant of the histamine-1 receptor (glu349asp) and body weight change during clozapine treatment", Psychiatr Genet, 12, pp.169~171 (2002)
- Lencz T, "DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia", Pharmacogenet Genomics, 20, pp.569~572 (2010)
- Vehof J, "Association of genetic variants of the histamine H1 and muscarinic M3 receptors with BMI and HbA1c values in patients on antipsychotic medication", Psychopharmacology, 216, pp.257~265 (2011)
- Park YM, "Weight gain associated with the alpha2a-adrenergic receptor -1,291 C", G polymorphism and olanzapine treatment, 2006, pp.141B, 394~397
- Mü~ller DJ, "The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia", Neurosci Lett, 379, pp.81~89 (2005)
- Bishop JR, "Pilot study of the G-protein beta3 subunit gene (C825T) polymorphism and clinical response to olanzapine or olanzapine-related weight gain in persons with schizophrenia", Med Sci Monit, 12, pp.BR47~BR50 (2006)
- Wang YC, "C825T polymorphism in the human G protein beta3 subunit gene is associated with long-term clozapine treatmentinduced body weight change in the Chinese population", Pharmacogenet Genomics, 15, pp.743~748 (2005)
- Ujike H, "Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients: a cohort study", J Clin Psychiatry, 69, pp.1416~1422 (2008)
- Zhang XY, "BDNF levels and genotype are associated with antipsychotic-induced weight gain in patients with chronic schizophrenia", Neuropsychopharmacology, 33, pp.2200~2205 (2008)
- Tiwari AK, "A common polymorphism in the cannabinoid receptor 1 (CNR1) gene is associated with antipsychoticinduced weight gain in Schizophrenia", Neuropsychopharmacology, 35, pp.1315~1324 (2010)
- Monteleone P, "Endocannabinoid Pro129Thr FAAH functional polymorphism but not 1359G", A CNR1 polymorphism is associated with antipsychotic-induced weight gain, 2010, pp.30, 441~445
- Perez-Iglesias R, "Effect of FTO, SH2B1, LEP, and LEPR polymorphisms on weight gain associated with antipsychotic treatment", J Clin Psychopharmacol, 30, pp.661~666 (2010)
- Lieberman JA, "Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia", N Engl J Med, 353, pp.1209~1223 (2005)
- Tiwari HK, "Association of allelic variation in genes mediating aspects of energy homeostasis with weight gain during administration of antipsychotic drugs (CATIE Study)", Front Genet, 2(56), pp.00056~ (2011)
- Chagnon YC, "A genome wide linkage study of obesity as secondary effect of antipsychotics in multigenerational families of eastern Quebec affected by psychoses", Mol Psychiatry, 9, pp.1067~1074 (2004)
- Chagnon YC, "Possible association of the pro-melaninconcentrating hormone gene with a greater body mass index as a side effect of the antipsychotic olanzapine", Am J Med Genet B Neuropsychiatr Genet, 144B, pp.1063~1069 (2007)
- Adkins DE, "Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs", Mol Psychiatry, 16, pp.321~332 (2011)
- Smith RC, "Allelic variation in ApoC3, ApoA5 and LPL genes and first and second generation antipsychotic effects on serum lipids in patients with schizophrenia", Pharmacogenomics J, 8, pp.228~236 (2008)
- de Leon J, "Exploring genetic variations that may be associated with the direct effects of some antipsychotics on lipid levels", Schizophr Res, 98, pp.40~46 (2008)
- FernøJ, "Antipsychotic drugs activate SREBPregulated expression of lipid biosynthetic genes in cultured human glioma cells: a novel mechanism of action?", Pharmacogenomics J, 5, pp.298~304 (2005)
- Le Hellard S, "Association between the insulininduced gene 2 (INSIG2) and weight gain in a German sample of antipsychotic-treated schizophrenic patients: perturbation of SREBP-controlled lipogenesis in drug-related metabolic adverse effects?", Mol Psychiatry, 14, pp.308~317 (2009)
- Tiwari AK, "Association study of polymorphisms in insulin induced gene 2 (INSIG2) with antipsychotic-induced weight gain in European and African-American schizophrenia patients", Hum Psychopharmacol, 25, pp.253~259 (2010)
- Newcomer JW, "Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review", CNS Drugs, 19(Suppl 1), pp.1~93 (2005)
- Yevtushenko OO, "Influence of 5-HT2C receptor and leptin gene polymorphisms, smoking and drug treatment on metabolic disturbances in patients with schizophrenia", Br J Psychiatry, 192, pp.424~428 (2008)
- Risselada AJ, "Association between HTR2C gene polymorphisms and the metabolic syndrome in patients using antipsychotics: a replication study", Pharmacogenomics J, 12, pp.62~67 (2012)
- Risselada AJ, "Association between the 1291-C", G polymorphism in the adrenergic α-2a receptor and the metabolic syndrome, 2010, pp.30, 667~671